Aquestive Therapeutics (AQST) Finished Goods (2017 - 2021)

Aquestive Therapeutics' Finished Goods history runs 5 years deep, the most recent figure standing at $1.0 million for Q1 2021.

• On a quarterly basis, Finished Goods rose 42.8% year-over-year to $1.0 million in Q1 2021; TTM through Mar 2021 was $1.0 million, a 42.8% increase from a year earlier, with the FY2020 full-year figure at $544000.0, up 4.82% from the prior year.
• Finished Goods improved to $1.0 million in Q1 2021 per AQST's latest filing, from $544000.0 in the prior quarter.
• Across five years, Finished Goods topped out at $1.3 million in Q2 2018 and bottomed at $519000.0 in Q4 2019.
• The 5-year median for Finished Goods is $1.0 million (2019), against an average of $958461.5.
• Across the five-year window, Finished Goods slumped 56.13% in 2019 and jumped 42.8% in 2021, its largest moves.
• Year by year, Finished Goods stood at $1.1 million in 2017, then rose by 11.18% to $1.2 million in 2018, then slumped by 56.13% to $519000.0 in 2019, then increased by 4.82% to $544000.0 in 2020, then surged by 84.01% to $1.0 million in 2021.
• Per Business Quant, the three latest AQST Finished Goods figures stand at $1.0 million (Q1 2021), $544000.0 (Q4 2020), and $858000.0 (Q3 2020).